Email updates

Keep up to date with the latest news and content from Arthritis Research & Therapy and BioMed Central.

This article is part of the supplement: 25th European Workshop for Rheumatology Research

Poster presentation

Expression of programmed death (PD)-1 and PD-1 ligands (PD-L1, PD-L2) in peripheral blood mononuclear cells of patients with systemic lupus erythematosus

G Bertsias, A Raptopoulou, E Coutala, M Mamoulaki, H Kritikos, P Sidiropoulos and DT Boumpas

Author Affiliations

Department of Rheumatology, Clinical Immunology and Allergy, Medical School, University of Crete, Greece

For all author emails, please log on.

Arthritis Research & Therapy 2005, 7(Suppl 1):P153  doi:10.1186/ar1674


The electronic version of this article is the complete one and can be found online at:


Received:11 January 2005
Published:17 February 2005

© 2005 BioMed Central Ltd

Background

Programmed death (PD)-1 is a newly described member of the immunoglobulin super-family that is expressed on activated T lymphocytes and B lymphocytes. Engagement of PD-1 with its specific ligands, PD-L1 (B7-H1) and PD-L2 (B7-DC), inhibits lymphocyte proliferation and cytokine expression, and may play a role in peripheral tolerance and negative regulation of T-cell and B-cell responses in vivo. We sought to investigate the expression profiles of PD-1 and PD-1 ligands in peripheral blood cells of patients with systemic lupus erythematosus (SLE).

Materials and methods

Blood was drawn from patients with SLE (n = 16), rheumatoid arthritis (n = 16), other inflammatory disease (n = 4), and healthy controls (n = 9). Peripheral blood mononuclear cells were separated on a ficoll-density gradient, and flow cytometry analysis was performed using monoclonal antibodies against CD3, CD19, CD14, CD25, CD69, PD-1, PD-L1, and PD-L2.

Results

See Table 1.

Conclusions

In this preliminary report, SLE patients showed a trend for lower expression of PD-1 and higher expression of PD-L1 in unstimulated peripheral blood mononuclear cells compared with other disease controls. These results corroborate findings linking SLE with polymorphism of the PD-1 gene resulting in putative altered expression of the PD-L2 [1]. Lower expression of PD-1 in SLE lymphocytes could be related to ineffective suppression of autoreactive lymphocytes and thus to disease evolution. Currently, we investigate expression of PD-1 and its ligands on subpopulations of lymphocytes (CD45RO+, CD27+), as well as the kinetics of expression upon stimulation.

References

  1. Prokunina L, Castillejo-Lopez C, Oberg F, Gunnarsson I, Berg L, Magnusson V, et al.: A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans.

    Nat Genet 2002, 32:666-669. PubMed Abstract | Publisher Full Text
{"cc_re__cc_re__cc_by_2_0": [">\r\n<meta name=\"dc.creator\" content=\"Boumpas, DT\" />\r\n<meta name=\"dc.source\" content=\"Arthritis Research & Therapy 2005 7:P153\" />\r\n<meta name=\"dc.format\" content=\"text/html\" />\r\n<meta name=\"dc.publisher\" content=\"BioMed Central Ltd\" />\r\n<meta name=\"dc.date\" content=\"2005-02-17\" />\r\n<meta name=\"dc.type\" content=\"Poster presentation\" />\r\n<meta name=\"dc.identifier\" content=\"10.1186/ar1674\" />\r\n<meta name=\"dc.language\" content=\"en\" />\r\n<meta name=\"dc.copyright\" content=\"2005 BioMed Central Ltd\" />\r\n<meta name=\"dc.rights\" content=\"http://creativecommons.org/licenses/by/2.0/\" />\r\n<meta name=\"dc.rightsAgent\" content=\"reprints@biomedcentral.com\" />\r\n\r\n<meta name=\"prism.issn\" content=\"1478-6354\" />\r\n<meta name=\"prism.publicationName\" content=\"Arthritis Research & Therapy\" />\r\n<meta name=\"prism.publicationDate\" content=\"2005-02-17\" />\r\n<meta name=\"prism.volume\" content=\"7\" />\r\n<meta name=\"prism.number\" content=\"Suppl 1\" />\r\n<meta name=\"prism.section\" content=\"Poster presentation\" />\r\n<meta name=\"prism.startingPage\" content=\"P153\" />\r\n<meta name=\"prism.copyright\" content=\"2"], "copyright__copyright__copyright": ["ive lymphocytes and thus to disease evolution. Currently, we investigate expression of PD-1 and its ligands on subpopulations of lymphocytes (CD45RO+, CD27+), as well as the kinetics of expression upon stimulation.\n\nReferences\n\n  1. Prokunina L, Castillejo-Lopez C, Oberg F, Gunnarsson I, Berg L, Magnusson V, et al.: A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans.\n\n    Nat Genet 2002, 32:666-669. PubMed\u00a0Abstract | Publisher\u00a0Full\u00a0Text", "ive lymphocytes and thus to disease evolution. Currently, we investigate expression of PD-1 and its ligands on subpopulations of lymphocytes (CD45RO+, CD27+), as well as the kinetics of expression upon stimulation.\n\nReferences\n\n  1. Prokunina L, Castillejo-Lopez C, Oberg F, Gunnarsson I, Berg L, Magnusson V, et al.: A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans.\n\n    Nat Genet 2002, 32:666-669. PubMed\u00a0Abstract | Publisher\u00a0Full\u00a0Text", "ive lymphocytes and thus to disease evolution. Currently, we investigate expression of PD-1 and its ligands on subpopulations of lymphocytes (CD45RO+, CD27+), as well as the kinetics of expression upon stimulation.\n\nReferences\n\n  1. Prokunina L, Castillejo-Lopez C, Oberg F, Gunnarsson I, Berg L, Magnusson V, et al.: A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans.\n\n    Nat Genet 2002, 32:666-669. PubMed\u00a0Abstract | Publisher\u00a0Full\u00a0Text", "ive lymphocytes and thus to disease evolution. Currently, we investigate expression of PD-1 and its ligands on subpopulations of lymphocytes (CD45RO+, CD27+), as well as the kinetics of expression upon stimulation.\n\nReferences\n\n  1. Prokunina L, Castillejo-Lopez C, Oberg F, Gunnarsson I, Berg L, Magnusson V, et al.: A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans.\n\n    Nat Genet 2002, 32:666-669. PubMed\u00a0Abstract | Publisher\u00a0Full\u00a0Text", "ive lymphocytes and thus to disease evolution. Currently, we investigate expression of PD-1 and its ligands on subpopulations of lymphocytes (CD45RO+, CD27+), as well as the kinetics of expression upon stimulation.\n\nReferences\n\n  1. Prokunina L, Castillejo-Lopez C, Oberg F, Gunnarsson I, Berg L, Magnusson V, et al.: A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans.\n\n    Nat Genet 2002, 32:666-669. PubMed\u00a0Abstract | Publisher\u00a0Full\u00a0Text"]}